Product Description
CDX-527 is the first candidate from Celldexs bispecific antibody platform. It uses Celldexs proprietary highly active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation, while preventing PD-1 inhibitory signals that subvert the immune response.
Mechanisms of Action: PD-1 Inhibitor, CD27 Inhibitor
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Celldex
Company Location: HAMPTON NJ 08827
Company CEO: Anthony S. Marucci
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Bladder Cancer|Breast Cancer|Cholangiocarcinoma|Colorectal Cancer|Esophageal Cancer|Fallopian Tube Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Liver Cancer|Non-Small-Cell Lung Cancer|Ovarian Cancer|Peritoneal Cancer|Renal Cell Carcinoma|Transitional Cell Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04440943 |
CDX527-01 | P1 |
Completed |
Ovarian Cancer|Esophageal Cancer|Fallopian Tube Cancer|Breast Cancer|Liver Cancer|Colorectal Cancer|Transitional Cell Carcinoma|Non-Small-Cell Lung Cancer|Cholangiocarcinoma|Bladder Cancer|Head and Neck Cancer|Peritoneal Cancer|Renal Cell Carcinoma|Gastrointestinal Cancer |
2023-04-06 |
23% |
2023-06-19 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/04/2021 |
News Article |
Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting |
|
04/12/2021 |
News Article |
Celldex Presents Promising Data from ILT4/PD-(L)1 Bispecific Antibody Program at AACR 2021 |
|
11/09/2020 |
News Article |
Celldex Presents Data from Oncology Portfolio at SITC 2020 |
|
08/24/2020 |
News Article |
Celldex Therapeutics Initiates Phase 1 Study of New Bispecific Product Candidate CDX-527 in Solid Tumors |